Clinical Study
Plasma Vascular Endothelial Growth Factor Dysregulation in Defining Aggressiveness of Head and Neck Squamous Cell Carcinoma
Table 3
sVEGFR-1 upregulation and VEGF suppression in association with clinicopathological parameters.
| | Parameter | sVEGFR-1 upregulation, (%) | VEGF suppression, (%) | | | | | | |
| | Control | 9 (52.9) | 8 (47.1) | — | 8 (44.4) | 10 (55.6) | — | | TNM stage | | | | | | | | I, II | 3 (33.3) | 6 (66.7) | 0.43 | 6 (50) | 6 (50) | 1 | | III, IV | 8 (17) | 39 (83) | 0.009 | 39 (78) | 11 (22) | 0.02 | | T stage | | | | | | | | T1,2 | 4 (26.7) | 11 (73.3) | 0.17 | 11 (57.9) | 8 (42.1) | 0.52 | | T3,4 | 7 (17) | 34 (83) | 0.009 | 34 (79) | 9 (21) | 0.01 | | Nodal status | | | | | | | | N− | 6 (26) | 17 (74) | 0.29 | 17 (58.6) | 12 (41.4) | 0.38 | | N+ | 5 (15.2) | 28 (84.8) | 0.008 | 28 (84.9) | 5 (15.1) | 0.003 | | Tumor grade | | | | | | | | G1,2 | 7 (25.9) | 20 (74.1) | 0.11 | 20 (58.8) | 14 (41.2) | 0.39 | | G3,4 | 4 (14) | 25 (86) | 0.007 | 25 (89.3) | 3 (10.7) | 0.002 |
|
|
*Comparison between tumor and normal controls.
|
